ALETA BIOTHERAPEUTICS
Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted. The company was founded in 2015 and is headquartered in Natick, Massachusetts, United States.
ALETA BIOTHERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2015-01-01
Address:
Natick, Massachusetts, United States
Country:
United States
Website Url:
http://www.aletabio.com
Total Employee:
1+
Status:
Active
Contact:
(508) 282-6370
Total Funding:
13.72 M USD
Technology used in webpage:
Organization Schema CrUX Dataset CrUX Top 50m
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Employees Featured
Founder
Investors List
Viva BioInnovator
Viva BioInnovator investment in Series A - Aleta Biotherapeutics
Advent Life Sciences
Advent Life Sciences investment in Venture Round - Aleta Biotherapeutics
Official Site Inspections
http://www.aletabio.com
- Host name: 198.49.23.144
- IP address: 198.49.23.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Aleta Biotherapeutics"
Aleta Biotherapeutics - Crunchbase Company Profile
Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.See details»
Aleta Biotherapeutics - LinkedIn
Aleta Biotherapeutics | 962 followers on LinkedIn. Aleta’s mission is to create cell therapeutics that provide robust and durable clinical benefit for patients. | Aleta’s mission is to create ...See details»
Aleta Biotherapeutics - PitchBook
Aleta Biotherapeutics General Information Description. Developer of immuno-oncology drugs intended to treat intractable cancerous tumors. The company's drugs transform cellular …See details»
Aleta Biotherapeutics and Cancer Research UK’s Centre …
Feb 21, 2024 NATICK, Mass. & LONDON, February 21, 2024--Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical TrialSee details»
Aleta Biotherapeutics Receives Innovation Passport …
Nov 7, 2022 Karen LaRochelle, MBA Chief Business Officer Aleta Biotherapeutics [email protected] Release Summary Aleta Biotherapeutics Receives Innovation Passport Designation for Biologic CAR T …See details»
Aleta BioTherapeutics | Viva BioInnovator
Viva BioInnovator. No. 50, Lane 63, Faraday Road, Zhangjiang High-Tech Park, Shanghai, 201203, China.See details»
Aleta Biotherapeutics - VentureRadar
"Aleta Biotherapeutics is an immuno-oncology company founded to transform cellular therapeutics to allow a broad spectrum of tumor types to be targeted, including currently intractable solid …See details»
Aleta Biotherapeutics and Cancer Research UK collaborate to …
NATICK, Mass., June 23, 2021 – Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a collaboration to advance the early phase clinical development of Aleta’s CAR-T …See details»
Aleta Biotherapeutics Receives Innovation Passport …
NATICK, Mass., November 7, 2022 – Aleta Biotherapeutics (Aleta), a privately held immuno-oncology company with novel biologic CAR T engagers that work in synergy with cell therapies to improve outcomes for patients, announces that …See details»
Aleta Biotherapeutics Receives Innovation Passport Designation …
Nov 7, 2022 Designation Intends to Accelerate Regulatory Review Process and Facilitate U.K. Patient Access to Medicines for Seriously Debilitating and Life-Threatening Diseases …See details»
Aleta Biotherapeutics to Present at Society for Immunotherapy of …
Oct 1, 2021 To discover more about our mission, technologies and pipeline please visit www.aletabio.com. Contacts. Media: Karen Sharma MacDougall 781-235-3060 …See details»
Aleta Biotherapeutics and Cancer Research UK ... - Business Wire
Jun 23, 2021 NATICK, Mass.--(BUSINESS WIRE)--Aleta Biotherapeutics (‘Aleta’) and Cancer Research UK today announced a collaboration to advance the early phase clinical …See details»
Aleta Biotherapeutics Announces ALETA-001 Presentation at 63
Nov 9, 2021 To discover more about our mission, technologies and pipeline please visit www.aletabio.com. To learn more about the work being done by Cancer Research UK please …See details»
Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization …
Aug 8, 2023 Aleta’s lead program, ALETA-001 has clinical support from collaborator Cancer Research UK, which will initiate the Phase 1/2 Clinical Trial during H2 2023 ALETA-001, …See details»
Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A
1 Aleta Biotherapeutics Inc., Natick, Massachusetts. [email protected]. 2 Aleta Biotherapeutics Inc., Natick, Massachusetts. PMID: 34253594 PMCID: PMC9398100 DOI: …See details»
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug ...
Feb 21, 2024 aletabio.com. About Cancer Research UK’s Centre for Drug Development. Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer …See details»
Aleta Biotherapeutics - Business Wire
Dec 7, 2019 Aleta Biotherapeutics today presented in vitro and in vivo results of novel CD19-anti-CD20 bridging protein technology at ASH 2019.See details»
News & Publications - Aleta Biotherapeutics
Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B …See details»